Hannah Khan, Aamir A Aziz, Humza Sulahria, Huma Khan, Abrahim Ahmed, Netan Choudhry, Raja Narayanan, Carl Danzig, Arshad M Khanani
{"title":"Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration.","authors":"Hannah Khan, Aamir A Aziz, Humza Sulahria, Huma Khan, Abrahim Ahmed, Netan Choudhry, Raja Narayanan, Carl Danzig, Arshad M Khanani","doi":"10.2147/OPTH.S367089","DOIUrl":null,"url":null,"abstract":"<p><p>Age-related macular degeneration (AMD) is characterized as a chronic, multifactorial disease and is the leading cause of irreversible blindness. Advanced AMD is classified as neovascular (wet) AMD and non-neovascular (dry) AMD. Dry AMD can progress to a more advanced form that manifests as geographic atrophy (GA), which significantly threatens vision, leading to progressive and irreversible loss of visual function. There are currently no approved therapeutics commercially available for GA patients. However, data from various clinical trials have demonstrated favorable results with significant reduction in GA lesion growth. This review furthers the understanding of the pathophysiology of GA, as well as current clinical trial data on investigational therapeutics.</p>","PeriodicalId":10442,"journal":{"name":"Clinical ophthalmology","volume":"17 ","pages":"321-327"},"PeriodicalIF":1.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/dc/opth-17-321.PMC9892637.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S367089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 4
Abstract
Age-related macular degeneration (AMD) is characterized as a chronic, multifactorial disease and is the leading cause of irreversible blindness. Advanced AMD is classified as neovascular (wet) AMD and non-neovascular (dry) AMD. Dry AMD can progress to a more advanced form that manifests as geographic atrophy (GA), which significantly threatens vision, leading to progressive and irreversible loss of visual function. There are currently no approved therapeutics commercially available for GA patients. However, data from various clinical trials have demonstrated favorable results with significant reduction in GA lesion growth. This review furthers the understanding of the pathophysiology of GA, as well as current clinical trial data on investigational therapeutics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
